First Read Pine Labs 1QFY27: Headline in-line; internals weak

Research evidence excerpt

First Read Pine Labs 1QFY27: Headline in-line; internals weak

on is separately disclosed in this document.

For financial instruments admitted to trading on a non-EU regulated market: UBS may act as a market maker save that where this activity is carried out in the US in accordance

with the definition given to it by the relevant laws and regulations, such activity will be specifically disclosed in this document. UBS may have issued a warrant the value of

which is based on one or more of the financial instruments referred to in the document. UBS and its affiliates and employees may have long or short positions, trade as

principal and buy and sell in instruments or derivatives identified herein; such transactions or positions may be inconsistent with the opinions expressed in this document.

Options and futures are not suitable for all investors, and trading in these instruments is considered risky and may be appropriate only for sophisticated investors. Prior to

buying or selling an option, and for the complete risks relating to options, you must receive a copy of "Characteristics and Risks of Standardized Options". You may read the

document at https://www.theocc.com/about/publications/character-risks.jsp or ask your financial advisor for a copy.

Investing in structured investments involves significant risks. For a detailed discussion of the risks involved in investing in any particular structured investment, you must read

the relevant offering materials for that investment. Structured investments are unsecured obligations of a particular issuer with returns linked to the performance of an

underlying asset. Depending on the terms of the investment, investors could lose all or a substantial portion of their investment based on the performance of the underlying

asset.